EC4 Real-World Healthcare Costs in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

Patients with classical Hodgkin lymphoma (cHL) relapsed or refractory (R/R) disease incur substantial healthcare resource utilization and costs. The PD-1 inhibitors nivolumab and pembrolizumab were approved by the FDA (May 2016 and March 2017, respectively) as treatments for R/R cHL patients; however, literature on the healthcare costs of patients treated with these two medications is sparse. This retrospective study evaluated the medical costs of patients with cHL initiated on pembrolizumab compared to nivolumab in the US.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research